Abstract

Hepatitis B (HBV) infection is a major public health concern. Perinatal transmission of HBV from mother to child represents the main mode of transmission. Despite the existence of effective immunoprophylaxis, the preventive strategy is inefficient in neonates born to mothers with HBV viral loads above 2 × 105 IU/mL. To prevent mother-to-child transmission, it is important to identify highly viremic pregnant women and initiate antiviral therapy to decrease their viral load. We developed a simple innovative molecular approach avoiding the use of automatic devices to screen highly viremic pregnant women. This method includes rapid DNA extraction coupled with an isothermal recombinase polymerase amplification (RPA) combined with direct visual detection on a lateral flow assay (LFA). We applied our RPA-LFA approach to HBV DNA-positive plasma samples with various loads and genotypes. We designed a triage test by adapting the analytical sensitivity to the recommended therapeutic decision threshold of 2 × 105 IU/mL. The sensitivity and specificity were 98.6% (95% CI: 92.7–99.9%) and 88.2% (95% CI: 73.4–95.3%), respectively. This assay performed excellently, with an area under the ROC curve value of 0.99 (95% CI: 0.99–1.00, p < 0.001). This simple method will open new perspectives in the development of point-of-care testing to prevent HBV perinatal transmission.

Highlights

  • Published: 2 March 2022Prevalence of hepatitis B (HBV) infection ranges worldwide from 0.5% to more than 7%in the WHO-defined African region [1,2]

  • The major risk of failure of this treatment is the presence of a high viral load in the pregnant woman [5–10]

  • Prevalence of HBs antigen positive (HBsAg+) pregnant women ranges from 3.2% in Eritrea, 4.8% in Burkina Faso to

Read more

Summary

Introduction

Published: 2 March 2022Prevalence of hepatitis B (HBV) infection ranges worldwide from 0.5% to more than 7%in the WHO-defined African region [1,2]. Prevalence of hepatitis B (HBV) infection ranges worldwide from 0.5% to more than 7%. The main long-term complications associated with chronic HBV infection are liver cirrhosis and hepatocarcinoma [2,3]. Deaths due to these complications increased by more than 33% between 1990 and 2013, with 821,000 deaths worldwide in 2019 [4]. To reduce incidence of mother-to-child HBV transmission (HBV MTCT), WHO recommends administration of HBV vaccine to all neonates and, in addition, recommends administration of immunoglobulins against HBV (HBIG) to neonates born to women infected with HBV within 12 h of delivery. Prevalence of HBs antigen positive (HBsAg+) pregnant women ranges from 3.2% in Eritrea, 4.8% in Burkina Faso to

Objectives
Methods
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call